Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 7/2015

01-07-2015 | Letter to the Editor

Evaluation of Kampo medicine in the clinical practice guideline for irritable bowel syndrome

Authors: Shin Fukudo, Hiroshi Kaneko, Hirotada Akiho, Masahiko Inamori, Yuka Endo, Toshikatsu Okumura, Motoyori Kanazawa, Takeshi Kamiya, Ken Sato, Toshimi Chiba, Kenji Furuta, Shigeru Yamato, Tetsuo Arakawa, Yoshihide Fujiyama, Takeshi Azuma, Kazuma Fujimoto, Tetsuya Mine, Soichiro Miura, Yoshikazu Kinoshita, Mamoru Watanabe, Kentaro Sugano, Tooru Shimosegawa

Published in: Journal of Gastroenterology | Issue 7/2015

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Motoo Y. Description of Kampo medicines in the clinical practice guideline for irritable bowel syndrome. J Gastroenterol. In press.
2.
Fukudo S, Kaneko H, Akiho H, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol. 2015;50:11–30.PubMedCrossRef
3.
Sasaki D, et al. Clinical efficacy of keishikashakuyakuto in patients with irritable bowel syndrome: a multicenter collaborative randomized controlled study. Rinsho To Kenkyu. 1998;75:1136–52 (Japanese).
4.
Ishii F, Iizuka B, Nagasako K, et al. Evaluations of the therapeutic efficacy of saikokeishito (TJ-10) versus keishikashakuyakuto (TJ-60) for irritable bowel syndrome and saireito (TJ-114) for ulcerative colitis. Prog Med. 1993;13:2893–900 (Japanese).
5.
Kux L. Department of Health and Human Services, Food and Drug Administration. [Docket no. FDA–2012–D–0146]. Guidance for industry on irritable bowel syndrome—clinical evaluation of drugs for treatment; availability. Fed Regist 2012;77:32124–32125.
6.
Qaseem A, Snow V, Owens DK, Shekelle P. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194–9.PubMedCrossRef
Metadata
Title
Evaluation of Kampo medicine in the clinical practice guideline for irritable bowel syndrome
Authors
Shin Fukudo
Hiroshi Kaneko
Hirotada Akiho
Masahiko Inamori
Yuka Endo
Toshikatsu Okumura
Motoyori Kanazawa
Takeshi Kamiya
Ken Sato
Toshimi Chiba
Kenji Furuta
Shigeru Yamato
Tetsuo Arakawa
Yoshihide Fujiyama
Takeshi Azuma
Kazuma Fujimoto
Tetsuya Mine
Soichiro Miura
Yoshikazu Kinoshita
Mamoru Watanabe
Kentaro Sugano
Tooru Shimosegawa
Publication date
01-07-2015
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 7/2015
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-015-1074-z

Other articles of this Issue 7/2015

Journal of Gastroenterology 7/2015 Go to the issue

Original Article—Liver, Pancreas, and Biliary Tract

Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy

Original Article—Alimentary Tract

Correlation between hypersensitivity induced by esophageal acid infusion and the baseline impedance level in patients with suspected gastroesophageal reflux

Original Article—Liver, Pancreas, and Biliary Tract

Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease

Original Article—Liver, Pancreas, and Biliary Tract

Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection

Review

Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa

Original Article—Liver, Pancreas, and Biliary Tract

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits